ArticleMolecular cancer therapeutics2011

Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration-resistant prostate cancer.

Daniel Gioeli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.